The DOI matches its Crossref record; 284 of the 286 references it cites were found in a registry or an index.
Guidelines for the treatment of Alzheimer’s disease from the Italian Association of Psychogeriatrics
Abstract
A committee of experts from the Italian Association of Psychogeriatrics compiled the following report, which was then approved by a Steering Committee (comprising 20 specialists in neurology, psychiatry or geriatrics) from the Association and by two Alzheimer associations representing patients and families: the Italian Association for Alzheimer's Disease and the Italian Federation for Alzheimer's Disease. The report is based on a comprehensive review of the scientific literature on the treatment of Alzheimer's disease, discusses methodological aspects of dementia management, and details the limitations of current therapies. These guidelines are, in general, consistent with the principles of evidence-based medicine; however, for some controversial or poorly investigated issues, the guidelines integrate scientific evidence with experience and opinions from experts working in the clinical setting. In particular, the clinical experience of experts has been used to define recommendations for starting and interrupting pharmacotherapy, and to critically review evidence about the efficacy of non-pharmacological interventions. The principal pharmacotherapeutic interventions covered in the guidelines are acetylcholinesterase inhibitors (donepezil, galantamine, rivastigmine, and tacrine) and memantine. The main non-pharmacological interventions reviewed are memory training, reality orientation therapy, and combined non-pharmacological interventions. Other issues covered are opportunities for Alzheimer's disease prevention, various modalities of care, and the treatment of comorbidities.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Input from consumers or consumer bodies (e.g., Kidney Health Australia, the Italian Association for Alzheimer's Disease) was explicit in nine guidelines [36, 38, 48–54].”
From Dementia Risk Reduction in Primary Care: A Scoping Review of Clinical Guidelines Using a Behavioral Specificity Framework (2022) · cites this paper as [53]
In the citing paper
“Four guidelines explicitly mentioned General Practitioners (GPs) as actors in reducing dementia risk [36, 38, 53, 57]; nurses were explicitly mentioned in six guidelines [2, 36, 38, 46, 48, 53].”
From Dementia Risk Reduction in Primary Care: A Scoping Review of Clinical Guidelines Using a Behavioral Specificity Framework (2022) · cites this paper as [53]
In the citing paper
“Guidelines recommending the management of risk factors typically suggested that healthcare professionals follow existing clinical guidelines for individual risk factors [2, 45, 51–53, 57].”
From Dementia Risk Reduction in Primary Care: A Scoping Review of Clinical Guidelines Using a Behavioral Specificity Framework (2022) · cites this paper as [53]
In the citing paper
“As Table 2 shows, discussion was the most commonly recommended action, mentioned by all but two guidelines [38, 53].”
From Dementia Risk Reduction in Primary Care: A Scoping Review of Clinical Guidelines Using a Behavioral Specificity Framework (2022) · cites this paper as [53]
In the citing paper
“It would technically be possible to follow five of the included guidelines without ever mentioning dementia to patients [38, 45, 52–54].”
From Dementia Risk Reduction in Primary Care: A Scoping Review of Clinical Guidelines Using a Behavioral Specificity Framework (2022) · cites this paper as [53]
In the citing paper
“Three included guidelines were over 10 years old and were either lacking in detail [38, 53] or referred to resources that were no longer available [57].”
From Dementia Risk Reduction in Primary Care: A Scoping Review of Clinical Guidelines Using a Behavioral Specificity Framework (2022) · cites this paper as [53]
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,401
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380
Shumaker, S. A., Legault, C., Rapp, S. R., Thal, L., Wallace, R. B., Ockene, J. K., Hendrix, S. L., Jones III, B. N., Assaf, A. R., Jackson, R. D., et al. (2003) · JAMA · doi:10.1001/jama.289.20.2651 · Cited by 2,178
An active and socially integrated lifestyle in late life might protect against dementia
Fratiglioni, L., Paillard-Borg, S., & Winblad, B. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00767-7 · Cited by 2,135
Petersen, R. C., Stevens, J. C., Ganguli, M., Tangalos, E. G., Cummings, J. L., & DeKosky, S. T. (2001) · Neurology · doi:10.1212/wnl.56.9.1133 · Cited by 2,065
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844
Research works printed but not linked: 14
- Lanct??t, 2003, CMAJ, 169, 557
- Corey-Bloom, 1998, Int J Geriatr Psychopharmacol, 1, 55
- Ditzler, 1991, Arzneimittelforschung, 41, 773
- Gerber, 1991, Hosp Community Psychiatry, 42, 843
- Heiss, 1994, Dementia, 5, 88
- Robb, 1986, Nurs Res, 35, 113
- Rozzini, 2003, Arch Intern Med, 163, 496
- Gil Gregorio, 2003, J Nutr Health Aging, 7, 304
- Buxbaum, 1, Front Biosci 2 Apr, 7, a50
- Knopman, 1985, Minn Med, 68, 687
- Freter, 1998, CMAJ, 159, 657
- Burge, 2003, Schweiz Rundsch Med Prax, 92, 1857
- van Hout, 2000, Br J Gen Pract, 50, 311
- Namazi, 1991, Am J Alzheimer??s Care Relat Disord Res, 6, 3
Cited by
Sorted by citations
O'Brien, J. T., Holmes, C., Jones, M. S., Jones, R. W., Livingston, G., McKeith, I. G., Mittler, P. J., Passmore, P., Ritchie, C. W., Robinson, L. A., et al. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881116680924 · Cited by 361
Efficacy of Music Therapy in the Treatment of Behavioral and Psychiatric Symptoms of Dementia
Raglio, A., Bellelli, G., Traficante, D., Gianotti, M., Ubezio, M. C., Villani, D., & Trabucchi, M. (2008) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181630b6f · Cited by 333
“Because of these difficulties, recent guidelines from national and international associations recommend that the pharmacologic approach should not be the first-line treatment.(3,6) Nonpharmacologic approaches are longtime known to be useful in the treatment of BPSD.”
BackgroundSeltzer, B. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.7.1011 · Cited by 260
“Guidelines published in several countries (see for example [170,171]) now recommend the routine use of cholinesterase inhibitors in at least some”
BackgroundAzermai, M., Petrović, M., Elseviers, M. M., Bourgeois, J., Bortel, L. M. V., & Stichele, R. V. (2011) · Ageing Research Reviews · doi:10.1016/j.arr.2011.07.002 · Cited by 197
Santo, S. G. D., Prinelli, F., Adorni, F., Caltagirone, C., & Musicco, M. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122140 · Cited by 186
Metadata
- Authors
- Caltagirone, C., Bianchetti, A., Luca, M. D., Mecocci, P., Padovani, A., Pirfo, E., Scapicchio, P., Senin, U., Trabucchi, M., & Musicco, M.
- Affiliations
- University of Rome Tor Vergata (IT)
- Gruppo di Ricerca Geriatrica (IT)
- University of Perugia (IT)
- University of Brescia (IT)
- University of Turin (IT)
- Institute of Biomedical Technologies (IT)
- Corresponding author
- Caltagirone, Carlo
- Venue
- Drugs & Aging
- Published
- 2005
- Volume
- 22
- Issue
- Suppl 1
- Pages
- 1???26
- ISSN
- 1170-229X (ISSN-L)
- OpenAlex
- W2057760116
- Cited by
- 55
- References
- 286
- Citations by year
- 2026: 1 · 2025: 2 · 2023: 1 · 2022: 3 · 2021: 4 · 2020: 1 · 2019: 1 · 2017: 3 · 2016: 1 · 2015: 2 · 2013: 1
- Type
- conference abstract
- Language
- en
- Open access
- closed
- Locations
- Drugs & Aging (publishedVersion)
- PubMed (publishedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, dementia management, acetylcholinesterase inhibitors, memantine, non-pharmacological treatment, memory training, reality orientation therapy, pharmacotherapy, Alzheimer's disease prevention, comorbidities, treatment guidelines
- MeSH terms
- Aged, Alzheimer Disease, Cholinesterase Inhibitors, Clinical Trials as Topic, Depressive Disorder, Humans, Italy, Memantine, Psychotherapy, Excitatory Amino Acid Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
